New imaging agent could sharpen cancer detection
NCT ID NCT07557225
First seen Apr 30, 2026 · Last updated Jun 02, 2026 · Updated 7 times
Summary
This study is testing a new imaging agent called 18F-T2, which is used in a PET/CT scan to find tumors that have high levels of a protein called CAIX. The goal is to see if this scan is better than standard scans at detecting and staging several types of cancer, including kidney, bladder, lung, and breast cancers. About 200 adults with suspected or confirmed solid tumors will receive the 18F-T2 injection and then be scanned. Researchers will also check for any side effects and measure the radiation exposure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, 100034, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.